BeOne’s lymphoma momentum accelerated with US accelerated approval for sonrotoclax (Beqalzi) in mantle cell lymphoma after BTK inhibitor therapy. The FDA’s decision gives BeOne a new commercial foothold and creates a potential combination rationale with BTK agents to improve durability in post-BTK MCL. The approval comes after the company’s early regulatory wins and supports a broader strategy of expanding BCL2 blockade beyond the initial labeled settings. For clinicians, the new option can alter treatment sequencing in a disease subtype where relapse after BTK blockade has become common. Investors are likely to focus on follow-up data expectations tied to confirmatory endpoints, which will determine how quickly accelerated approval can move toward full approval.